Pharmacoeconomics: theory and practice
№2, 2022, Vol.10

The purpose of the study was to conduct an organizational and economic assessment of preferential drug provision for patients suffering from diabetes mellitus (DM) in the Rostov region. Materials and methods. During the study, monitoring data of the Ministry of Health of the Rostov Region on the implementation of preferential drug provision were used. Methods of structural-logical, comparative analysis and determination of average indicators were used. Conclusion. An organizational and economic assessment of preferential drug provision (LLO) of patients suffering from diabetes in the Rostov region was carried out. A description of the number of patients entitled to state support measures in terms of drug provision was given. It was found that only about 20% of the federal beneficiaries retained the right to receive medicines at the expense of the federal budget. For drug therapy of patients, 9 schemes are used Treatment, medical care in the region for patients with diabetes is provid- ed by 191 endocrinologists, as well as therapists and pediatricians, 199 endo- crinological beds have been deployed for patients with severe complications of the consequences of diabetes. The financial costs of LPOs from the regional budget exceed almost 2 times the costs of federal beneficiaries, the number of which is almost three times less than the number of regional ones. The cost per regional beneficiary is 12,099.19 rubles, which is 21.9% higher than the cost of a beneficiary under a federal benefit (9926.9 rubles). When studying the cost structure of hypoglycemic drugs, the predominance of costs for in- sulin analogues in the range was established. It should be pointed out that, in addition to hypoglycemic drugs, beneficiaries are provided with test strips for determining blood sugar levels at home and consumables for insulin pumps.

INTRODUCTION. One of the socially significant directions in the development of pharmaceutical products is the provision of high-quality, effective and safe medicines intended for the treatment of orphan (rare) diseases among the population of the Member States of the Union. The availability of medicinal products for such patients suffering from such diseases should be regulated by state incentives for the development and launch of orphan drugs from do- mestic manufacturers through the updating and timely updating of regulatory legal acts in the field of marketing authorization (MA) of medicinal products, as well as providing benefits when initiating the registration process. AIM. To assess the prospects and possibilities of putting orphan drugs into circulation within the framework of the Eurasian Economic Union for domestic manufacturers. MATERIALS AND METHODS. The study materials were available publications in peer-reviewed journals on thematic queries based on keywords of the se- lected topic, official websites, regulatory legal acts, regulating the procedure for registering medicinal products in the Eurasian Economic Union and the Russian Federation. RESULTS AND DISCUSSION. A review of national legislation on MA and regulation of the circulation of orphan drugs revealed several critical problems that prevent domestic manu- facturers from introducing drugs of this group to the pharmaceutical market of the Eurasian Economic Union, such as lack of regulation of the list of orphan drugs and a simplified registration procedure in the custom territory of the Eurasian Economic Union, complexity procedures for assigning an orphan drug status, etc. Imperfections in the regulatory regulation of these issues predetermine problems in drug provision for patients with orphan diseases in the Eurasian Economic Union. Conclusion. A review of the problems and possibilities of putting orphan drugs into circulation by domestic manufacturers needs to improve legal regulation both at the level of the Russian Federation and within the legal framework of the Eurasian space.

Goal. To study the indicators characterizing the program of preferential medication provision in the Tyumen region for persons suffering from acute cardiovascular diseases for the period 2020-2022. In particular, the structure and amount of funds from the budgets of all levels allocated for the provision of medication care to this category of patients, the number of citizens included in the regional Register of persons who have had acute cardiovascular diseases, the number of provided prescriptions for preferential medication provision, their average cost. To identify the main trends in the development of a new strand in the preferential provision of medicines for patients of medical organizations in the Tyumen region. Materials and methods. In the study of indicators, methods were used: situational-logical, content analysis, structural, system, computer technologies. Results. The organization of a new strand of preferential medication provision for people who have suffered acute cerebrovascular accident, myocardial infarction and other diseases has been studied. An analysis of the regulatory and legal regulation of preferential medication provision, indicators affecting the availability of medication care to patients of medical organizations based on monitoring stocks of medicines, their receiving by pharmacies, prescribing and dispensing necessary medicines was carried out. Conclusion. The Program of preferential provision of necessary medicines is being implemented at the expense of the federal (27%) and regional (73%) budgets in Tyumen region for providing primary health care to the patients who have suffered acute cardiovascular diseases. Indicators of medicine provision (program funding, number of prescriptions provided, average prescription cost) are dynamic, tend to grow and indicate the availability of medication care